Pharmacy Acquisition Multiples in 2026: EBITDA & Revenue

The Two Valuation Frameworks: Revenue Multiple vs. EBITDA Multiple

Pharmacy acquisitions use two parallel valuation frameworks, and buyers need to understand both.

**Revenue multiple (0.5x–1.5x):** The simpler framework, used for quick screening and for deals where EBITDA margins are compressed. A pharmacy doing $1.6M in revenue at a 0.6x multiple = $960K. Revenue multiples are less precise because two pharmacies with identical revenue can have very different profitability depending on PBM contract terms, DIR fee exposure, and dispensing cost structure.

**EBITDA multiple (3x–6x):** More accurate for pricing but requires clean financials. A pharmacy with $300K EBITDA at 4.5x = $1.35M. EBITDA-based pricing requires normalizing for owner salary (market rate for a pharmacy owner/operator who works full-time is $120K–$150K/year), adding back one-time expenses, and adjusting for DIR fee timing differences.

**The practical answer:** Start with the revenue multiple for initial screening, then build an EBITDA model for LOI pricing. If the revenue multiple and EBITDA multiple produce significantly different numbers (more than 20% apart), dig into why — it usually signals either unusual margin compression or an anomaly in cost structure.

For a buyer evaluating pharmacy opportunities, see the pharmacy acquisition guide for sourcing and deal structuring.

PBM Risk: DIR Fees, Network Exclusions, and EBITDA Volatility

Pharmacy Benefit Manager (PBM) contracts are the single biggest risk factor in independent pharmacy valuations. DIR fees (Direct and Indirect Remuneration) were the dominant PBM risk in 2020–2023, and despite CMS rule changes taking effect in 2024, PBM contract risk hasn't gone away.

**How DIR fees worked:** PBMs retroactively clawed back dispensing fees from pharmacies based on performance metrics — medication adherence, generic dispensing rate, immunization rates. A pharmacy might receive a $7 dispensing fee at the point of sale, then have $2–$4 clawed back months later when the PBM settled annual DIR calculations. This made EBITDA unpredictable and cash flow management difficult.

**Post-2024 CMS reform:** CMS implemented rules requiring PBMs to reflect DIR fees at the point of sale rather than retroactively. This improves cash flow predictability but doesn't eliminate PBM risk — network exclusions, preferred network tiering, and contract renegotiations remain major variables.

**Network exclusion risk:** PBMs periodically restructure their preferred pharmacy networks. Being excluded from a preferred network means patients using that PBM pay higher out-of-pocket costs at your pharmacy — driving them to competitors. A pharmacy excluded from a major PBM preferred network can lose 20–30% of script volume within 12 months. During diligence, verify current network status for all major PBMs (CVS Caremark, Express Scripts, OptumRx) and ask about any notices received regarding network contract modifications.

**Due diligence implication:** Request trailing 12-month DIR fee activity, current PBM contract status for all major plans, and any network performance improvement plan (PIP) notices. A pharmacy under a PIP is a yellow flag — it may face exclusion if metrics don't improve.

• Request trailing 12-month DIR fee reconciliation from each PBM
• Verify current preferred network status for CVS Caremark, Express Scripts, OptumRx
• Check for any Performance Improvement Plan (PIP) notices in last 24 months
• Review PBM contract renewal dates — contracts expiring within 12 months of close carry renegotiation risk
• Analyze EBITDA margin quarterly to identify DIR timing impact on cash flow

Script Count as the Primary Value Driver

Script count is the most important operational metric in pharmacy valuation. Everything else flows from it.

**Volume benchmarks:** - Under 100 scripts/day: Sub-economic, very limited buyer interest, typically 2.5x–3x EBITDA if profitable at all - 100–200 scripts/day: Entry level independent, 3x–4x EBITDA, attractive to first-time pharmacy buyers - 200–350 scripts/day: Core independent pharmacy range, 3.5x–4.5x EBITDA, most transactions happen here - 350–500 scripts/day: Premium independent, 4.5x–5.5x EBITDA, strong buyer interest from small chains - 500+ scripts/day: Chain-level volume at independent economics, 5x–6x+ EBITDA if margins are healthy

**Script count trend matters more than absolute number:** A pharmacy at 280 scripts/day and growing 8% annually is worth more than one at 310 scripts/day that's been flat for three years. Request 3 years of monthly script counts — not just the trailing 12-month summary — to see the trend.

**Specialty script premium:** A pharmacy with 15–20% of volume in specialty medications (oncology, HIV, immunology, rare disease) commands a premium. Specialty prescriptions have higher dispensing fees and are more defensible than commodity generics. A pharmacy with a specialty volume of 30+ specialty scripts/day may trade at 5.5x–7x EBITDA with the right buyer.

**Prescription retention after ownership change:** Historical data shows pharmacies lose 8–15% of scripts in the 6 months following an ownership change. Factor this into your EBITDA projections. Buyers who budget for a 10% script loss and model EBITDA accordingly avoid the shock that causes some buyers to feel they overpaid.

DEA Registration Transfer: Timing and Process

The DEA registration is the most operationally critical license in a pharmacy acquisition. Without it, you cannot dispense controlled substances — which means you effectively cannot operate as a pharmacy.

**DEA registration is entity-specific:** Like PE/LS licenses in engineering, a DEA registration belongs to the legal entity, not the individual. In an asset sale, the buyer's new entity must obtain a fresh DEA registration. The seller's DEA registration terminates at close.

**Timeline:** A new DEA registration application typically takes 45–90 days. There is no way to expedite this. This is the deal timeline constraint that buyers most often fail to plan for.

**The practical closing structure:** Close the business acquisition (transfer assets, take possession) but delay dispensing controlled substances until the new DEA registration is active. During the gap, the pharmacy can dispense non-controlled medications. In practice, most pharmacies have enough non-controlled volume to continue operating during the DEA gap — but understand what percentage of your target pharmacy's volume is Schedule II–V before assuming this is manageable.

**DEA transfer in stock sales:** In a stock sale, the existing DEA registration remains with the entity — it doesn't transfer or need to be reissued. This is one of the strongest arguments for a stock sale in pharmacy acquisitions, particularly for pharmacies with high controlled substance volume.

**Notification requirement:** Even in a stock sale, a change of ownership requires notification to the DEA within 30 days. Failure to notify is a DEA violation. Build this into your closing checklist.

For full SBA financing structure around DEA timing, see SBA loans for pharmacy acquisitions.

340B Program Eligibility: Revenue Upside or Complexity?

The 340B drug pricing program allows eligible covered entities (hospitals, FQHCs, clinics serving low-income populations) to purchase drugs at significant discounts, then dispense them at standard reimbursement — capturing the margin spread. Contract pharmacies (independent pharmacies that have 340B agreements with covered entities) participate in this margin.

**The revenue upside:** A pharmacy with one or more active 340B contract pharmacy agreements can generate $50K–$300K/year in additional net revenue depending on volume and drug mix. This incremental revenue is high-margin — the pharmacy is dispensing drugs purchased at 340B pricing and reimbursed at Medicare/Medicaid rates.

**How to evaluate 340B status:** Ask the seller to provide copies of all 340B covered entity agreements, trailing 12-month 340B program revenue, and the status of each agreement. 340B covered entities can terminate contract pharmacy agreements with 30–60 days notice — it's important to understand how stable these agreements are.

**340B risk factors:** CMS and HHS have been tightening 340B program requirements. Drug manufacturers have been restricting 340B pricing to in-house dispensing, reducing contract pharmacy eligibility for certain drugs. A buyer paying a premium for 340B revenue should model a stress scenario where 20–30% of 340B volume is lost due to manufacturer restrictions.

**For buyers:** 340B program participation is a potential upside, not a baseline. Don't capitalize 340B revenue at the same multiple as core dispensing revenue. Treat it as a 2x–3x EBITDA add-on at most.

Buyer Types and Their Price Tolerance

Understanding who else is bidding on a pharmacy determines how aggressive you need to be on price and speed.

**Independent owner-operators:** First-time buyers, often current pharmacist employees looking to own. Price range: 3x–4.5x EBITDA, SBA financed. Move slowly, require longer diligence. Represent the majority of transactions under $1.5M.

**Small regional chains (2–10 locations):** Buying for geographic expansion. They know their unit economics well and will pay a premium for the right location — 4x–5.5x EBITDA for a clean asset in their target market. They move faster than individual buyers and often have banking relationships that let them close in 60 days.

**PBM-backed buyers:** CVS, Walgreens, and Rite Aid acquire independents primarily to add script volume and DEA registration capacity. They pay 4x–6x EBITDA for high-volume pharmacies in their network. The trade-off for sellers: these buyers convert your independent to their brand immediately, ending any legacy you built.

**Private equity:** PE interest in the sub-$5M pharmacy space is limited but growing. PE firms focused on pharmacy roll-ups target platforms at $2M+ EBITDA. Individual independents below this threshold are add-on acquisitions rather than platforms.

For a detailed comparison of independent vs. chain pharmacy valuation dynamics, see independent pharmacy vs. chain valuation.